Arm D

DRUG4 trials

Sponsors

Shandong Suncadia Medicine Co., Ltd., Hoffmann La Roche, University College London, EFFECT HOPE CANADA

Conditions

CancerLeprosy, Buruli Ulcer and Lymphatic Filariasis Mental and Behavioural Disorders Skin and Connective Tissue DiseasesTuberculosisType 2 Diabetes

Phase 1

A HR20031 BE Study on Healthy Subjects

CompletedNCT05682495

Shandong Suncadia Medicine Co., Ltd.Type 2 Diabetes

Start: 2023-01-31End: 2023-04-04Updated: 2023-04-07

Phase 2

Platform Assessing Regimens And Durations In a Global Multisite Consortium for TB [PARADIGM4TB (UNITE4TB – 01)]

Active, not recruitingPACTR202403493915530

University College LondonTuberculosis

Start: 2024-04-15Target: 2500Updated: 2026-09-14

Phase 3

A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer (ProHer)

RecruitingPACTR202211579014330

Hoffmann La RocheCancer

Start: 2022-07-05Target: 330Updated: 2026-08-03

Unknown Phase

Active, not recruitingPACTR202404852537141

EFFECT HOPE CANADALeprosy, Buruli Ulcer and Lymphatic Filariasis Mental and Behavioural Disorders Skin and Connective Tissue Diseases

Start: 2022-10-01Target: 200Updated: 2026-09-14

Related Papers

Reassessing the Significance of Mycobacterium in Neglected Tropical Diseases: A Study Protocol in Nigeria

International Journal of Mycobacteriology2024-10-01